-
公开(公告)号：US20240082325A1
公开(公告)日：2024-03-14
申请号：US18510979
申请日：2023-11-16
Applicant: BioGaia AB
Inventor： Stefan Roos , Wolfgang Kunze , John Bienenstock
IPC: A61K35/747 , A61K35/745 , A61P1/00
CPC classification number: A61K35/747 , A61K35/745 , A61P1/00
Abstract: A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.
-
公开(公告)号：US20190112676A1
公开(公告)日：2019-04-18
申请号：US16217507
申请日：2018-12-12
Applicant: BioGaia AB
Inventor： Eamonn Connolly , Wolfgang Kunze , John Bienenstock
IPC: C12R1/225 , A61K49/00 , C12N1/20 , A61K35/74 , A61K35/747 , G06T7/00 , A23L33/135
Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.
-
公开(公告)号：US20210154245A1
公开(公告)日：2021-05-27
申请号：US17045315
申请日：2020-04-17
Applicant: BioGaia AB
Inventor： Stefan Roos , Wolfgang Kunze , John Bienenstock
IPC: A61K35/747 , A61K35/745 , A61P1/00
Abstract: A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.
-
公开(公告)号：US09816150B2
公开(公告)日：2017-11-14
申请号：US15389577
申请日：2016-12-23
Applicant: BioGaia AB
Inventor： Eamonn Connolly , Wolfgang Kunze , John Bienenstock
IPC: C12R1/225 , A23L33/135 , A61K35/747
CPC classification number: C12R1/225 , A23L33/135 , A23V2002/00 , A61K35/74 , A61K35/747 , A61K49/0004 , A61K2035/11 , C12N1/20 , G06T7/0012 , G06T2207/30092
Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, comprising: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyze the effect of the agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyze the effect of the agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of the bacterial strains in the treatment of intestinal motility disorders are also provided.
-
5.发明申请Method for Selection of Agents Influencing Intestinal Motility Disorders and Pain 有权选择影响肠运动障碍和疼痛的药物的方法公开(公告)号：US20150231186A1
公开(公告)日：2015-08-20
申请号：US14425470
申请日：2013-09-03
Applicant: BioGaia AB
Inventor： Eamonn Connolly , Wolfgang Kunze , John Bienenstock
CPC classification number: C12R1/225 , A23L33/135 , A23V2002/00 , A61K35/74 , A61K35/747 , A61K49/0004 , A61K2035/11 , C12N1/20 , G06T7/0012 , G06T2207/30092
Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.
Abstract translation: 提供了一种用于评估用于治疗不同肠蠕动障碍的药剂的方法，使用与大脑连通的胃肠道的肌肉和神经相关的不同方法学部分。 特别地，本发明提供了选择有效治疗肠蠕动障碍的药剂的方法，其中所述方法包括：a）在胃肠道段进行的时空（ST）测绘步骤，以分析其作用 所述药物对胃肠蠕动的影响; 和b）在胃肠道段进行的离体神经束记录步骤，以分析所述药物对肠系膜传入神经发生的作用。 还提供了通过本发明的方法选择的细菌菌株和所述细菌菌株用于治疗肠蠕动障碍的用途。
-
Patent Agency Ranking
公开(公告)号：US20200225214A1
公开(公告)日：2020-07-16
申请号：US16834278
申请日：2020-03-30
Applicant: BIOGAIA AB
Inventor： Eamonn Conolly , Wolfgang Kunze , John Bienenstock
Abstract: The present embodiments relate to selection of agents effective in reducing or preventing gastrointestinal pain in a subject. Such an agent is selected and identified if it is capable of reducing spontaneous and/or induced transient receptor potential vanilloid 1 (TRPV1) activation.
-
公开(公告)号：US20160334391A1
公开(公告)日：2016-11-17
申请号：US15111930
申请日：2015-01-23
Applicant: BIOGAIA AB
Inventor： Eamonn Conolly , Wolfgang Kunze , John Bienenstock
CPC classification number: G01N33/5041 , A61K35/74 , A61K45/06 , A61K2035/11 , G01N33/6872 , G01N33/6893 , G01N2333/705 , G01N2800/06
Abstract: The present embodiments relate to selection of agents effective in reducing or preventing gastrointestinal pain in a subject. Such an agent is selected and identified if it is capable of reducing spontaneous and/or induced transient receptor potential vanilloid 1 (TRPV1) activation.
Abstract translation: 本实施方案涉及选择有效减少或预防受试者胃肠道疼痛的药剂。 如果能够减少自发和/或诱导的瞬时受体电位香草素1（TRPV1）激活，则选择和鉴定这样的药剂。
-
公开(公告)号：US11857582B2
公开(公告)日：2024-01-02
申请号：US17045315
申请日：2020-04-17
Applicant: BioGaia AB
Inventor： Stefan Roos , Wolfgang Kunze , John Bienenstock
IPC: A61K35/747 , A61P1/00 , A61K35/745
CPC classification number: A61K35/747 , A61K35/745 , A61P1/00
Abstract: A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.
-
公开(公告)号：US20220306984A1
公开(公告)日：2022-09-29
申请号：US17840923
申请日：2022-06-15
Applicant: BioGaia AB
Inventor： Eamonn Connolly , Wolfgang Kunze , John Bienenstock
IPC: C12N1/20 , A61K49/00 , G06T7/13 , A61K35/74 , G06T7/00 , A23L33/135 , A61K35/747
Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.
-
公开(公告)号：US11371985B2
公开(公告)日：2022-06-28
申请号：US16834278
申请日：2020-03-30
Applicant: BIOGAIA AB
Inventor： Eamonn Conolly , Wolfgang Kunze , John Bienenstock
Abstract: The present embodiments relate to selection of agents effective in reducing or preventing gastrointestinal pain in a subject. Such an agent is selected and identified if it is capable of reducing spontaneous and/or induced transient receptor potential vanilloid 1 (TRPV1) activation.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.015 seconds)
